Cover Image

Bosentan and sildenafil in the treatment of HIV-associated pulmonary hypertension

Pierangelo Chinello, Stefania Cicalini, Andrea Cortese, Maria Paola Cicini, Nicola Petrosillo
  • Pierangelo Chinello
    Second Infectious Diseases Unit, L. Spallanzani National Institute for Infectious Diseases, Rome, Italy | pierangelo.chinello@inmi.it
  • Stefania Cicalini
    Second Infectious Diseases Unit, L. Spallanzani National Institute for Infectious Diseases, Rome, Italy
  • Andrea Cortese
    U.O. Diagnostica per Immagini, S. Camillo-Forlanini Hospital, Rome, Italy
  • Maria Paola Cicini
    III Cardiology Unit, S. Camillo-Forlanini Hospital, Rome, Italy
  • Nicola Petrosillo
    Second Infectious Diseases Unit, L. Spallanzani National Institute for Infectious Diseases, Rome, Italy

Abstract

We present the case of an HIV/HCV-coinfected patient with HIV-related pulmonary hypertension (HRPH) who experienced a good clinical and functional response to bosentan, with a subsequent switch to oral sildenafil due to increased transaminase levels. Bosentan resulted less handy in this case, probably due to both side effects and co-morbidities.

Keywords

bosentan; sildenafil; HIV; pulmonary arterial hypertension

Full Text:

PDF
Submitted: 2011-08-11 17:47:31
Published: 2011-11-22 14:19:00
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views: 3

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


 

 

Infectious Disease Reports [eISSN 2036-7449] is a new Open Access, online-only, peer-reviewed journal published by PAGEPress®, Pavia, Italy. All credits and honors to PKP for their OJS.

 

 

 

 
 
© PAGEPress 2008-2015     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185